ArticleMedicine2026
Primary pulmonary mucosa-associated lymphoid tissue lymphoma presenting as a right hilar mass: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
rationalePrimary pulmonary lymphoma (PPL) is an extremely rare malignant lung tumor that is frequently misdiagnosed as pneumonia or lung cancer due to its atypical radiological and clinical presentation. The rationale of this report is to elucidate the diagnostic value of combining computed tomography (CT) and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in evaluating a rare presentation of PPL. PATIENT CONCERNS: A 44-year-old male was admitted after an incidental lung lesion was discovered during routine screening. He was completely asymptomatic, lacking respiratory or systemic "B symptoms." DIAGNOSES: A baseline chest CT identified a 3.9 × 3.5 cm soft-tissue mass in the right hilar region that compressed the right upper lobe bronchus, leading to secondary post-obstructive consolidation that lacked the characteristic air bronchogram sign. The CT also revealed an incidental 2.6 × 2.6 cm anterior mediastinal nodule. Subsequent whole-body 18F-FDG PET/CT demonstrated intense tracer uptake in the right hilar mass with a maximum standardized uptake value of 7.1 and mild-to-moderate uptake in an adjacent regional lymph node (maximum standardized uptake value of 3.2). The scan showed completely absent uptake in the anterior mediastinal nodule and the post-obstructive consolidation, arguing against metabolically active malignancy in those areas. Histopathological and immunohistochemical analysis from a bronchoscopic transbronchial lung biopsy confirmed primary pulmonary mucosa-associated lymphoid tissue lymphoma.
interventionsThe patient underwent localized radiotherapy targeting the right hilar mass and the FDG-avid regional hilar/posterior mediastinal lymph node. A total dose of 66 Gy was delivered in 18 fractions over the course of 3 weeks. OUTCOMES: At the 2-month post-discharge follow-up, a repeat chest CT revealed a marked reduction in the size of both the hilar lesion and the regional lymph nodes. The patient remained completely asymptomatic, and his laboratory parameters normalized. LESSONS: Differentiating PPL from central lung cancer and coexisting benign mediastinal abnormalities presents a significant clinical challenge, particularly when atypical radiological features mimic aggressive carcinomas. Whole-body 18F-FDG PET/CT serves as an invaluable, noninvasive modality for metabolic characterization, accurate loco-regional staging, and preventing clinical overstaging by effectively differentiating metabolically active lymphoma from concurrent benign lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.